Patent Assignment
Reel/Frame 069894/0045
Security Interest
Recorded: 2025-01-14
Pages: 41
Assignor
INHIBRX BIOSCIENCES, INC.
Executed: 2025-01-13
Assignees
OXFORD FINANCE LLC
115 SOUTH UNION STREET, SUITE 300, ALEXANDRIA, VIRGINIA, 22314
OXFORD FINANCE LLC
115 SOUTH UNION STREET, SUITE 300, ALEXANDRIA, VIRGINIA, 22314
Covered Properties
(62)
PDL1-Binding Proteins
Multivalent and Multispecific 41BB-Binding Fusion Proteins
Multivalent and Multispecific 41BB-Binding Proteins
Uses of PDL1-Binding Proteins
Application:
18/956,693 →
Publication:
US 2025/0250349
5T4 Single Domain Antibodies and Therapeutic Compositions Thereof
CD123-Binding Polypeptides and Uses Thereof
CD123-Binding Polypeptides and Uses Thereof
CD28 Single Domain Antibodies and Multivalent and Multispecific Constructs Thereof
Multispecific Polypeptide Constructs Having Constrained CD3 Binding and Methods of Using the Same
Multispecific Polypeptide Constructs Having Constrained CD3 Binding and Methods of Using the Same
Application:
18/520,308 →
Publication:
US 2024/0101704
Multispecific Polypeptide Constructs Having Constrained CD3 Binding and Related Methods and Uses
Multispecific Polypeptide Constructs Containing a Constrained CD3 Binding Domain and a Receptor Binding Region and Methods of Using the Same
Multispecific Polypeptide Constructs Containing a Constrained CD3 Binding Domain and a Receptor Binding Region and Methods of Using the Same
Application:
18/969,101 →
Publication:
US 2025/0092137
CD33-Binding Polypeptides and Uses Thereof
CD33-Binding Polypeptides and Uses Thereof
CD33-Binding Polypeptides and Uses Thereof
Application:
18/792,984 →
Publication:
US 2025/0059279
CD33 Targeted Immunotherapies
CD47 Antibodies and Methods of Use Thereof
CD47 Antibodies and Methods of Use Thereof
Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
Application:
18/451,025 →
Publication:
US 2024/0166744
CD8-Binding Polypeptides and Uses Thereof
Application:
18/578,133 →
CD8-Targeted Modified IL-2 Polypeptides and Uses Thereof
Application:
18/578,137 →
CLEC12a Binding Polypeptides and Uses Thereof
CLEC12a Binding Polypeptides and Uses Thereof
Application:
18/748,655 →
Publication:
US 2025/0011436
Cll-1 Targeted Immunotherapies
Canine PD-1-Binding Polypeptides and Uses Thereof
Application:
17/922,569 →
Publication:
US 2023/0331846
DLL3 Single Domain Antibodies and Therapeutic Compositions Thereof
Multivalent and Multispecific DR5-Binding Fusion Proteins
Multivalent and Multispecific DR5-Binding Fusion Proteins and Methods of Treating Neoplasms
Multivalent and Multispecific DR5-Binding Fusion Proteins and Methods of Modulating Immune Cells
Multivalent and Multispecific DR5-Binding Fusion Proteins
Application:
18/626,699 →
Publication:
US 2024/0376220
Formulations of DR5 Binding Polypeptides
Application:
18/264,475 →
DR5 Agonist and PLK1 Inhibitor or CDK Inhibitor Combination Therapy
Application:
18/853,278 →
Publication:
US 2025/0215101
DR5 Agonist and IAP Antagonist Combination Therapy
Application:
18/865,854 →
Publication:
US 2025/0302948
Non-Immunogenic Single Domain Antibodies
Non-Immunogenic Single Domain Antibodies
Application:
18/807,532 →
Publication:
US 2025/0223338
FcRn-Binding Polypeptides and Uses Thereof
Application:
18/871,526 →
Multispecific Gitr-Binding Fusion Proteins and Methods of Use Thereof
Albumin-Binding Polypeptides and Uses Thereof
Application:
18/861,746 →
Publication:
US 2025/0277018
Ige Binding Proteins and Uses Thereof
Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
Application:
17/418,458 →
Publication:
US 2022/0089667
Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
Application:
18/002,613 →
Publication:
US 2023/0235005
NKp46-Binding Polypeptides and Uses Thereof
Application:
18/685,665 →
Publication:
US 2025/0136681
NKp46-Targeted Modified IL-2 Polypeptides and Uses Thereof
Application:
18/685,666 →
Publication:
US 2024/0376198
Multivalent and Multispecific OX40-Binding Fusion Proteins
Multivalent and Multispecific OX40-Binding Fusion Proteins
OX40-Binding Polypeptides and Uses Thereof
OX40-Binding Polypeptides and Uses Thereof
OX40-Binding Polypeptides and Uses Thereof
Pd-1 Single Domain Antibodies and Therapeutic Compositions Thereof
Pd-1 Single Domain Antibodies and Therapeutic Compositions Thereof
PD-1 Single Domain Antibodies and Therapeutic Compositions Thereof
Siglec-8 Binding Proteins and Uses Thereof
Application:
18/923,531 →
Publication:
US 2025/0042997
Gamma Delta T-Cell-Binding Polypeptides and Uses Thereof
Application:
18/726,347 →
Publication:
US 2025/0066477
Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
Application:
18/726,350 →
Publication:
US 2025/0109203
Type Iii Secretion System Targeting Molecules
Type III Secretion System Targeting Molecules
Multivalent and Multispecific Glucocorticoid-Induced Tnfr-Related Protein (Gitr)-Binding Single-Domain Antibody Fusion Proteins and Encoding Nucleic Acids
B7H3 Single Domain Antibodies and Therapeutic Compositions Thereof
Application:
17/283,902 →
Publication:
US 2023/0124851
Ige Binding Proteins and Uses Thereof
PCT:
PCT/US2024/037846 ↗
OX40 Agonist Therapy
PCT:
PCT/US2023/073279 ↗
OX40 Agonist Therapy
PCT:
PCT/US2024/016505 ↗
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jul 10, 2013
From: ECKELMAN, BRENDAN; TIMMER, JOHN; RAZAI, AMIR; DEVERAUX, QUINN
To: INHIBRX LLC
Reel/Frame 030766/0522 →
Assignment of Assignor's Interest
Jun 26, 2017
From: ECKELMAN, BRENDAN P.; TIMMER, JOHN C.; HATA, CHELSIE; JONES, KYLE S.
To: INHIBRX LP
Reel/Frame 042816/0394 →
Merger and Change of Name
May 22, 2018
From: INHIBRX LP; TENIUM THERAPEUTICS, INC.
To: INHIBRX, INC.
Reel/Frame 046215/0084 →
Merger and Change of Name
May 23, 2018
From: INHIBRX, LP; TENIUM THERAPEUTICS, INC.
To: INHIBRX, INC.
Reel/Frame 046216/0820 →
Corrective Assignment to Correct the Receiving Party Address Change Previously Recorded at Reel: 046216 Frame: 0820. Assignor(S) Hereby Confirms the Assignment.
Jul 2, 2018
From: INHIBRX, LP
To: INHIBRX, INC.
Reel/Frame 046635/0320 →
Assignment of Assignor's Interest
Sep 7, 2018
From: ECKELMAN, BRENDAN P.; KAPLAN, MICHAEL D.; WILLIS, KATELYN M.; DEVERAUX, QUINN
To: INHIBRX, INC.
Reel/Frame 046813/0110 →
Assignment of Assignor's Interest
Sep 4, 2019
From: RASCON, LUCAS
To: INHIBRX, INC.
Reel/Frame 050267/0097 →
Merger
Oct 25, 2019
From: INHIBRX, LP
To: INHIBRX, INC.
Reel/Frame 050890/0760 →
Change of Name
Oct 25, 2019
From: INHIBRX, LLC
To: INHIBRX, LP
Reel/Frame 050832/0610 →
Assignment of Assignor's Interest
Nov 1, 2019
From: ECKELMAN, BRENDAN P.; KAPLAN, MICHAEL D.; WILLIS, KATELYN M.; DEVERAUX, QUINN
To: INHIBRX, INC.
Reel/Frame 050895/0085 →
Assignment of Assignor's Interest
Aug 5, 2021
From: TIMMER, JOHN C.; KAPLAN, MICHAEL D.; WILLIS, KATELYN M.; PANDIT, RAJAY A.
To: INHIBRX, INC.
Reel/Frame 057097/0600 →
Intellectual Property Security Agreement
Feb 28, 2022
From: INHIBRX, INC.
To: OXFORD FINANCE LLC
Reel/Frame 059262/0780 →
Assignment of Assignor's Interest
Mar 7, 2022
From: JARJOUR, JORDAN; POGSON, MARK; LEUNG, WAI-HANG
To: 2SEVENTY BIO, INC.
Reel/Frame 059181/0749 →
Assignment of Assignor's Interest
Sep 1, 2022
From: JONES, KYLE; CRAGO, WILLIAM; SANABRIA, ANGELICA; HOLLANDS, ANDREW
To: INHIBRX, INC.
Reel/Frame 060970/0188 →
Assignment of Assignor's Interest
Oct 25, 2022
From: TIMMER, JOHN C.; JACKSON, RUTGER H.; WILLIS, KATELYN M.; CRAGO, WILLIAM S.
To: INHIBRX, INC.
Reel/Frame 061533/0509 →
Assignment of Assignor's Interest
Jul 5, 2023
From: ECKELMAN, BRENDAN P.; KAPLAN, MICHAEL D.; WILLIS, KATELYN M.; TIMMER, JOHN C.
To: INHIBRX, INC.
Reel/Frame 064156/0732 →
Assignment of Assignor's Interest
Mar 19, 2024
From: MACEDO, CHELSIE; JONES, KYLE; CRAGO, WILLIAM; HOLLANDS, ANDREW
To: INHIBRX, INC.
Reel/Frame 066819/0457 →
Assignment of Assignor's Interest
Apr 22, 2024
From: 2SEVENTY BIO, INC.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 067184/0147 →
Assignment of Assignor's Interest
May 22, 2024
From: JONES, KYLE; CRAGO, WILLIAM; SANABRIA, ANGELICA; HOLLANDS, ANDREW
To: INHIBRX, INC.
Reel/Frame 067493/0933 →
Release of Security Interest
Jun 3, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: INHIBRX, INC.
Reel/Frame 067606/0247 →
Assignment of Assignor's Interest
Jun 10, 2024
From: INHIBRX, INC.
To: INHIBRX BIOSCIENCES, INC.
Reel/Frame 067680/0770 →
Assignment of Assignor's Interest
Jun 10, 2024
From: INHIBRX, INC.
To: INHIBRX BIOSCIENCES, INC.
Reel/Frame 067679/0635 →
Assignment of Assignor's Interest
Jun 10, 2024
From: INHIBRX, INC.
To: INHIBRX BIOSCIENCES, INC.
Reel/Frame 067679/0338 →
Assignment of Assignor's Interest
Aug 26, 2024
From: ECKELMAN, BRENDAN P.; KAPLAN, MICHAEL D.; WILLIS, KATELYN M.; DEVERAUX, QUINN
To: INHIBRX, INC.
Reel/Frame 068401/0809 →
Assignment of Assignor's Interest
Nov 14, 2025
From: INHIBRX, INC.
To: INHIBRX BIOSCIENCES, INC.
Reel/Frame 074249/0831 →